Document Detail

Hydroxyurea promotes the reduction of spontaneous BFU-e to normal levels in SS and S/beta thalassemic patients.
MedLine Citation:
PMID:  11300342     Owner:  NLM     Status:  MEDLINE    
We have studied the effects of hydroxyurea on growth and differentiation of early erythroid progenitor cells (BFU-e) from peripheral blood of sickle cell disease patients (five SS and two Hb S/beta-thalassemia) in the presence or absence of exogenous stimulating factors. When the mononuclear cells from the sickle cell disease patients were cultured at diagnosis (before hydroxyurea treatment), there was an increased number of BFU-e in relation to controls (p < 0.05, Wilcoxon test) when cells were grown in the presence or absence of 5637 conditioned medium and erythropoietin. Colonies that developed in the absence of added growth factors were considered "spontaneous". A significant difference was observed after hydroxyurea treatment in the number of BFU-e obtained in the presence and absence of stimulus, with a higher reduction in the spontaneous BFU-e number. As expected, there was an increased Hb F level in these patients when compared with their pretreatment levels. There was no correlation between spontaneous BFU-e and hemoglobin levels in all patients studied.
C Bincoletto; R C Perlingeiro; S T Saad; F F Costa; M L Queiroz
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hemoglobin     Volume:  25     ISSN:  0363-0269     ISO Abbreviation:  Hemoglobin     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-04-12     Completed Date:  2001-09-13     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7705865     Medline TA:  Hemoglobin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-7     Citation Subset:  IM    
Department of Pharmacology, Hemocentre, State University of Campinas, UNICAMP, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Sickle Cell / blood*,  drug therapy,  pathology
Antisickling Agents / pharmacology*,  therapeutic use
Blood Cell Count
Cell Differentiation / drug effects
Cell Division / drug effects
Cells, Cultured / drug effects
Culture Media, Conditioned / pharmacology
Erythroid Precursor Cells / drug effects*
Erythropoietin / pharmacology
Hydroxyurea / pharmacology*,  therapeutic use
Sickle Cell Trait / blood*,  drug therapy,  pathology
beta-Thalassemia / blood*,  drug therapy,  pathology
Reg. No./Substance:
0/Antisickling Agents; 0/Culture Media, Conditioned; 11096-26-7/Erythropoietin; 127-07-1/Hydroxyurea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinoma...
Next Document:  Prenatal diagnosis of beta-thalassemia major by high-performance liquid chromatography analysis of h...